sellModerate cluster of 5
Andrew S. Davis sold $94k of SILK
Chief Commercial Officer at Silk Road Medical Inc. 5,481 shares at an average of $17.17, traded Mar 5, 2024, filed Mar 5, 2024.
Warning score
40Value
$94k
5,481 shares
Holdings after
287,773
-2% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +10Trade size$94k at market
- 0Share of holdings soldSold 1.9% of holdings
- +15Cluster5 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001593968-24-000434, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 1, 2024 | AGrant or award Common Stock | +62,201 | $0.00 | $0 | 293,254 | Mar 5, 2024 |
| Mar 5, 2024 | SOpen-market sale Common Stock | -5,481 | $17.17 | $94k | 287,773 | Mar 5, 2024 |
Related signals
Other insiders at Silk Road Medical Inc and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 37Weak | SILKbuy Silk Road Medical Inc | Kevin J. Ballinger director | $199k 11,700 shares | +192% | |
| 48Moderate | Silk Road Medical Inc | Lucas W. Buchanan COO/CFO | $170k 9,877 shares | -2% | |
| 36Weak | Silk Road Medical Inc | Marie L. Jones VP, Finance and CAO | $45k 2,602 shares | -3% | |
| 36Weak | Silk Road Medical Inc | Kevin M Klemz EVP/Chief Legal Officer/Sec. | $43k 2,497 shares | -1% | |
| 38Weak | Silk Road Medical Inc | Richard Ruedy EVPClin&Reg.Affairs&QA | $65k 3,800 shares | -2% | |
| 18Weak | Silk Road Medical Inc | Richard Ruedy EVPClin&Reg.Affairs&QA | $67k 3,000 shares | -2% | |
| 15Weak | SILKsell Silk Road Medical Inc | Marie L. Jones CAO and VP, Finance | $4,334 656 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.